AbbVie shares slide on sliding Humira revenue; Deerfield is making a big investment in new device startups

→ AbbVie triggered alarm bells on Wall Street today as the pharma company cited biosimilar competition in Europe for a steep decline in expected Humira revenue. Shares $ABBV dropped 7% on the news. Sales in Europe are expected to drop 30% this year, though so far AbbVie has been able to retain market exclusivity for the mega-blockbuster in the US for some years to come.

→ Deerfield Management and Stan Rowe have created a new device incubator called NXT Biomedical. The incubator plans to invest up to $25 million over the next 5 years and Deerfield — a prolific investor — will allocate up to $250 million for 5 to 8 startup companies that emerge from the incubator.

→ Chinese regulators have OK’d a new indication for Amgen’s PCSK9 drug Repatha, adding marketing authorization for atherosclerotic cardiovascular disease to reduce the risk of myocardial infarction, stroke and coronary revascularization.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,400+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->